Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$18.88M+57115.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey T. Finer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 134
- Beta
- 2.20
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 6.04
Financials
Revenue
$18.88M+57115.2%Net Income
$-26.59MEBITDA
$-21.97MFree Cash Flow
$-13.89MEPS (diluted)
$-0.57Shares Outstanding (diluted)
46.91M+140.6%Operating Expenses
$46.11MCash & Debt
$478.60MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $45.95M | $-48.88M | $-1.10 |
| 2024 | $1.07M | $-71.80M | $-1.93 |
| 2023 | $151.0K | $4.18M | $0.03 |
Valuation
SEPNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+100.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·11d ago·Positive
… with SEP-479 as the primary catalyst and a strong cash runway into 2029. SEP-479's Phase 1 readout in 1Q27 could provide the first meaningful clinical validation of SEPN's GPCR platform, with safety and key biomarker data in focus. SEP-204 is expected to enter Phase 1 in 1Q27, offering a differentiated oral approach for Graves' disease and thyroid eye disease with promising preclinical selectivity.
View source ↗ - Newszacks.com·13d ago·Negative
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates Septerna, Inc. (SEPN) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.09 per share a year ago.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…humans Phase 1 clinical trial initiation planned for the first quarter of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the selection of SEP-204 as its potential first-in-class development candidate for the treatment of Graves' disease and thyroid eye disease (TED) and reported initial preclinical data ahead of a pos…
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Septerna to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026: Guggenheim 3rd Annual Healthcare Innovation Conference – Boston Fireside chat on Tuesday, November 10, 2026, at 10:00 a.m.
View source ↗ - Newsglobenewswire.com·82d ago·Negative
Septerna to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:
View source ↗ - Newszacks.com·104d ago·Neutral
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.56 per share a year ago.
View source ↗
Earnings
Mon, Mar 8(in 4 months)
Consensus estimate $-0.57 per share
Typical surprise -20.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.57 vs $-0.41miss
- Mon, Aug 10$-0.29 vs $-0.43beat
- Tue, May 12$-0.19 vs $-0.51beat
- Mon, Mar 9$-0.24 vs $-0.23miss
- Mon, Nov 10$-0.09 vs $0.19miss
- Mon, Aug 11$-0.56 vs $-0.05miss
Estimates and results for SEPN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SEPN officers and directors.
- Bought
- —
- Sold
- $81.7m
0 trades
43 trades
- Labrucherie Gil Msold
- Labrucherie Gil Msold
- Labrucherie Gil Msold
- Finer Jeffreysold
- Finer Jeffreysold
- Finer Jeffreysold
- Finer Jeffreysold
- Finer Jeffreysold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SEPN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
